Stock Analiz

Lucid Diagnostics Inc. LUCD

Medical/Dental Instruments · IPO 2021 · data as of November 13, 2026

$0.45Market cap $93M
Open the interactive analysis →

Lucid Diagnostics Inc. (LUCD) is a healthcare company listed in the US with a market value of about $93M. In the twelve months to September 30, 2026 it had revenue of $5M and net income of -$61M, a net margin of -1127.2%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -164%.

About Lucid Diagnostics

Lucid Diagnostics is listed in the US and classified in medical/dental instruments, IPO year 2021. Revenue went from $500000 in 2021 to $5M in 2025, growth of about 75.2% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 182% over three years (dilution for shareholders). It spends 121% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health0/5
Shareholder returns0/5

Checks passed

  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S17.1
P/B15.7
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-55.8%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)8.3%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-4992.9%
ROIC (5-yr avg.)-164.2%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$5M$5M$4M$2M$377000$500000—
Net income-$61M-$58M-$46M-$53M-$56M-$28M-$8M
Free cash flow-$52M-$47M-$44M—-$33M-$19M—
EPS (diluted)$-0.38$-0.34$-0.53$-0.63$-0.78$-0.76$-0.29
Net margin-1127.2%-1232.7%-1047.6%-2169.1%-14899.5%-5615.6%—
ROIC—-135.1%-172.8%-295.9%-177.4%-39.6%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 5 analysts is $4.00, 791% above the current price; targets range from $2.00 to $9.50; the consensus rating is “Strong buy”; expected EPS is $-0.24 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Lucid Diagnostics pay a dividend?

Not currently.

Is Lucid Diagnostics a good stock to buy?

We do not give buy or sell advice. Lucid Diagnostics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.